Category Archives: News

Gut microbiome plays a crucial role in modulation of inflammatory and immune pathways. Diverse bacterial species from gut microbiota feed on specific prebiotics (non-digestible dietary fibers) producing metabolites, such as short chain fatty acids (SCF… Continue reading →

Inflammatory bowel disease (IBD) comprises a group of intestinal disorders, including ulcerative colitis and Crohn’s disease. Intestinal fibrosis, as result of chronic inflammation, is a common complication in IBD. High treatment failure rates associat… Continue reading →

Internally penetrating Crohn’s disease (CD) complications (IPCDC; i.e. abscess and/or inflammatory mass) confer significant morbidity to pediatric patients with CD. Management strategies are heterogenous. Anti-tumor-necrosis-factor-a biologics (anti-TN… Continue reading →

Endoscopic assessment of disease severity is a key component of ulcerative colitis (UC) clinical studies. However, interobserver variability may contribute to bias in selecting study candidates and evaluating response rates. Scoring by blinded central … Continue reading →

Crohn’s Disease (CD) is a chronic granulomatous inflammatory disease involving any section of the gastrointestinal (GI) tract. Metastatic Crohn’s Disease (MCD) is a rare extraintestinal manifestation of CD defined as cutaneous granulomatous lesions non… Continue reading →

Crohn’s disease (CD) has been known to cause transmural inflammation of the gastrointestinal wall with manifestations including ulcers, abscesses, and fistula. Peptic ulcer disease (PUD) is most commonly caused by Non-Steroid Anti-Inflammatory Drugs (N… Continue reading →

Societal guidelines recommend against the use of 5-aminosalicylate (5-ASA) therapy for pediatric patients with Crohn’s Disease (pCD). Previous trials showed no benefit of 5-ASAs for inducing remission and similar one-year relapse rates when compared wi… Continue reading →

Treatment of Crohn’s disease (CD) may require biologics. Dose escalation may be necessary to maintain efficacy, while adverse events or non-response may lead to treatment discontinuation. This analysis aimed to generate real-world evidence of persisten… Continue reading →

A treat-to-target (TTT) strategy of aiming for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest. We sought to assess the feasibility of… Continue reading →

Intestinal fibrosis is a serious complication of Crohn’s disease (CD) and is caused by the excess deposition of extracellular matrix protein. There are no therapies to prevent or treat this and surgical intervention remains the only treatment option. N… Continue reading →